Published in Best Pract Res Clin Haematol on December 01, 2008
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55
Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science (2002) 5.47
Germline KRAS mutations cause Noonan syndrome. Nat Genet (2006) 4.48
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet (2004) 4.45
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell (2010) 4.11
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood (2007) 3.11
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 3.00
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood (2003) 2.76
Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 2.54
CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood (2012) 2.51
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood (2004) 2.42
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood (2007) 2.30
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood (2005) 1.96
K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood (2006) 1.93
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc (2007) 1.89
Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell (2006) 1.88
Cancer predisposition and hematopoietic failure in Rad50(S/S) mice. Genes Dev (2002) 1.87
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood (2013) 1.85
High-throughput mapping of origins of replication in human cells. EMBO Rep (2007) 1.75
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature (2009) 1.72
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med (2011) 1.72
Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol (2009) 1.67
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev (2010) 1.66
MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene (2002) 1.62
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell (2012) 1.61
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood (2010) 1.60
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A (2002) 1.57
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer (2006) 1.54
Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell (2006) 1.53
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest (2012) 1.52
DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res (2010) 1.49
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun (2012) 1.49
Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev (2007) 1.48
A critical role for Apc in hematopoietic stem and progenitor cell survival. J Exp Med (2008) 1.42
Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol (2007) 1.41
Use of a donor heart with symptomatic WPW in an alternate donor program. J Heart Lung Transplant (2002) 1.39
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood (2006) 1.35
Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood (2007) 1.33
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol (2007) 1.31
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood (2002) 1.25
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A (2010) 1.25
Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood (2010) 1.21
ERK8, a new member of the mitogen-activated protein kinase family. J Biol Chem (2002) 1.21
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res (2013) 1.19
Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood (2006) 1.17
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A (2002) 1.16
Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res (2006) 1.16
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med (2010) 1.15
Percutaneous epicardial mapping during ablation of difficult accessory pathways as an alternative to cardiac surgery. Heart Rhythm (2004) 1.15
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol (2013) 1.15
Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov (2013) 1.13
Pre-replication complex proteins assemble at regions of low nucleosome occupancy within the Chinese hamster dihydrofolate reductase initiation zone. Nucleic Acids Res (2010) 1.13
Activation of Wnt/β-catenin protein signaling induces mitochondria-mediated apoptosis in hematopoietic progenitor cells. J Biol Chem (2012) 1.10
Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood (2013) 1.10
MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2012) 1.09
Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact (2005) 1.09
Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact (2009) 1.08
Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood (2011) 1.08
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood (2005) 1.08
Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat (2008) 1.07
Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm. Mediterr J Hematol Infect Dis (2011) 1.07
Targeting Ras in myeloid leukemias. Clin Cancer Res (2008) 1.07
Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: a prospective 5-year follow-up study. Exp Hematol (2002) 1.06
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood (2009) 1.06
Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood (2006) 1.06
The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer (2004) 1.05
Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood (2006) 1.05
Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors. Cancer Res (2002) 1.04
Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res (2002) 1.03
β-Catenin induces T-cell transformation by promoting genomic instability. Proc Natl Acad Sci U S A (2013) 1.03
Common fragile sites are characterized by histone hypoacetylation. Hum Mol Genet (2009) 1.02
De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet (2007) 1.02
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.01
Targeting oncogenic Ras. Genes Dev (2007) 1.01
Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood (2002) 1.00
Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. Sci Signal (2013) 0.98
Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis. Blood (2013) 0.97
Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics (2005) 0.96
Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08. J Pediatr Hematol Oncol (2004) 0.96
Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer (2006) 0.93
Genetic pathways leading to therapy-related myeloid neoplasms. Mediterr J Hematol Infect Dis (2011) 0.93
Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res (2011) 0.93
Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer Genet Cytogenet (2007) 0.93
RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer (2004) 0.92
The role of comprehensive cancer centers in survivorship care. Cancer (2013) 0.91